1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea…
<!-- Name:DistributionId Value:8823565 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Samsung Bioepis
Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar, EPYSQLI™
<!-- Name:DistributionId Value:8799603 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Samsung Bioepis Presents Phase 1 Study Results of SB17 (Ustekinumab), A Proposed…
<!-- Name:DistributionId Value:8789635 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Samsung Bioepis Presents Data from its Ophthalmology Biosimilar Portfolio at American…
SB15, a proposed biosimilar to EYLEA, showed equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetics profile to reference aflibercept in the Phase 3 study interim…
Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5 in…
Long term follow-up data from British Association of Dermatologics and Immunomodulators Register (BADBIR) shows safety and effectiveness of SB5 in patients with psoriasis who have started…
Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed…
Phase 3 study demonstrated clinical equivalence in efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of SB12 compared to reference eculizumab in paroxysmal…
Samsung Bioepis Celebrates 10 Years of Realizing Passion for Health, Innovating…
Holds a virtual ceremonial event for the first time to mark the anniversary with its global employees Pledges to keep innovating access to biologic medicines worldwide INCHEON, Korea,…
Longest Follow-Up Data on Trastuzumab Biosimilar Presented at 2021 SABCS
Five-year follow-up results reconfirm comparable long-term efficacy of SB3 (ONTRUZANT®, trastuzumab-dttb) versus Herceptin® through additional analysis with a larger group of patients with…